The Pharmacological Chaperone 1-Deoxygalactonojirimycin Reduces Tissue Globotriaosylceramide Levels in a Mouse Model of Fabry Disease-Reference-Cited by-同舟云学术

The Pharmacological Chaperone 1-Deoxygalactonojirimycin Reduces Tissue Globotriaosylceramide Levels in a Mouse Model of Fabry Disease

Published:2010-01 Issue:1 Volume:18 Page:23-33
ISSN:1525-0016
Container-title:Molecular Therapy
language:en
Short-container-title:Molecular Therapy

Author:

Khanna Richie,Soska Rebecca,Lun Yi,Feng Jessie,Frascella Michelle,Young Brandy,Brignol Nastry,Pellegrino Lee,Sitaraman Sheela A,Desnick Robert J,Benjamin Elfrida R,Lockhart David J,Valenzano Kenneth J

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology,Genetics,Molecular Biology,Molecular Medicine

Reference50 articles.

1. Human Gene Mutation Database (HGMD): 2003 update;Stenson;Hum Mutat,2003

2. Fabry disease: an asymptomatic hemizygote with significant residual α-galactosidase A activity;Bishop;Am J Hum Genet,1981

3. Synthesis and processing of alpha-galactosidase A in human fibroblasts. Evidence for different mutations in Fabry disease;Lemansky;J Biol Chem,1987

4. An atypical variant of Fabry's disease with manifestations confined to the myocardium;von Scheidt;N Engl J Med,1991

5. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency;Brady;N Engl J Med,1967

Cited by 122 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Terra incognita of glial cell dynamics in the etiology of leukodystrophies: Broadening disease and therapeutic perspectives;Life Sciences;2024-10

2. A Systematic Review on Safety and Efficacy of Migalastat for the treatment of Fabry’s Disease;Expert Opinion on Pharmacotherapy;2024-04-12

3. Therapeutic applications of carbohydrate-based compounds: a sweet solution for medical advancement;Molecular Diversity;2024-03-30

4. Anderson–Fabry disease management: role of the cardiologist;European Heart Journal;2024-03-15

5. Overexpression of VEGFα as a biomarker of endothelial dysfunction in aortic tissue of α-GAL-Tg/KO mice and its upregulation in the serum of patients with Fabry’s disease;Frontiers in Cardiovascular Medicine;2024-02-05